Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Website: pfizer.com


  • Bad financial results growth rate -11.2% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (-1.7%)
  • Dividend yield for the last twelve months 6.7%
  • Free cash flow yield 8.9% (LTM)
  • Share price is 18.8% higher than minimum and 52.9% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (13.2x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: PFE
Share price, USD:  (0.0%)25.65
year average price 26.33  


year start price 29.10 2024-07-15

max close price 31.39 2024-07-30

min close price 21.59 2025-04-10

current price 25.65 2025-07-14
Common stocks: 5 615 000 000

Dividend Yield:  6.7%
FCF Yield LTM: 8.9%
EV / LTM EBITDA: 13.2x
EV / EBITDA annualized: 10.7x
Last revenue growth (y/y):  -7.8%
Last growth of EBITDA (y/y):  -14.6%
Historical revenue growth:  -7.3%
Historical growth of EBITDA:  +3.9%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 144 025
Net Debt ($m): 45 091
EV (Enterprise Value): 189 116
EBITDA LTM ($m): 14 282
EV / LTM EBITDA: 13.2x
Price to Book: 1.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-07-11zacks.com

Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?

2025-07-10businesswire.com

XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

2025-07-04247wallst.com

Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (July 2025)

2025-07-03seekingalpha.com

Pfizer: Options Activity Speaks Bullish

2025-07-03zacks.com

Pfizer Trades Above 50-Day Average for a Month: Time to Buy?

2025-07-02zacks.com

Pfizer (PFE) Outperforms Broader Market: What You Need to Know

2025-06-29prnewswire.com

XtalPi and Pfizer Expand Strategic Collaboration to Advance AI-Driven Drug Discovery and Materials Science Simulations

2025-06-27zacks.com

PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal

2025-06-25seekingalpha.com

Pfizer Could Be The Turnaround Story In The Pharmaceutical Space

2025-06-25businesswire.com

Pfizer Declares Third-Quarter 2025 Dividend
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data